Quanterix Corporation
HealthcareNASDAQ:QTRX · NASDAQ Global Market
+$0.07 today
Vol 0.70M · Avg 1.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-36.2%
avg -29.7%
ROIC
-29.8%
avg -108.7%
ROA
-25.6%
avg -42.4%
Analysis
ROA is currently the strongest return metric at -25.6% versus its period average of -42.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Everett V. Cunningham | President, Chief Executive Officer & Director | $1.23M | — | 60 | $0.00 | <0.01% |
Vandana Sriram | Chief Financial Officer & Treasurer | $787,227.00 | — | 52 | $34,866.00 | 0.07% |
William Donnelly | Executive Chair | $258,643.00 | — | 64 | $154,127.00 | 0.33% |
David R. Walt | Co-Founder & Chairman of Scientific Advisory Board | $50,937.00 | — | 73 | $1.87M | 3.98% |
Daniel S. Char | Chief Legal Officer & Corporate Secretary | — | — | 65 | $0.00 | <0.01% |
Naren Bhat | Senior Vice President of Corporate Development & Strategy | — | — | — | — | — |
Erica Bell | Chief People Officer | — | — | 53 | — | — |
Michael Miller | Chief Technology & Products Officer | — | — | 62 | $33,834.00 | 0.07% |
Anthony Catalano | Chief Operating Officer | — | — | — | — | — |
Benjamin Meadows | Chief Commercial Officer | — | — | 46 | $3,500.00 | <0.01% |
Joshua Young | Head of Investor Relations | — | — | — | — | — |
Jerzy Olejnik | Chief Technology Officer | — | — | — | — | — |
Laurie A. Churchill | Senior Vice President, General Counsel & Secretary | — | — | 55 | $13,738.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$790,376.14
Sells
0
$0.00
Net Sentiment
+$790,376.14
Net buying
Most Active
Meadows Benjamin
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| May 12, 2026 | Meadows Benjamin Direct | Buy | 3.5K | $2.77 | $9,695.00 | |
| Sep 12, 2025 | Sriram Vandana Direct | Buy | 4.2K | $4.79 | $19,878.50 | |
| Jun 13, 2025 | WALT DAVID R Direct | Buy | 124.0K | $6.14 | $760,802.64 |
Analysis
Insiders reported 3 buys worth $790,376.14 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $790,376.14. Meadows Benjamin was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +47.8% | +15.2% (11yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +47.8% over three years. Forward estimates point to Revenue at +15.2% (11yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Viemed Healthcare, Inc.
NASDAQ:VMD
$400.62M
908 Devices Inc.
NASDAQ:MASS
$312.72M
Senseonics Holdings, Inc.
NASDAQ:SENS
$299.93M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.12M
Inogen, Inc.
NASDAQ:INGN
$173.28M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
CVRx, Inc.
NASDAQ:CVRX
$133.48M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
Outset Medical, Inc.
NASDAQ:OM
$83.23M
Who manages QTRX?
Quanterix Corporation (QTRX) lists 13 active executives. The top listed executive is Daniel S. Char, Chief Legal Officer & Corporate Secretary.
Are QTRX insiders buying or selling?
Recent insider activity shows net buying of $9.21M.
Explore More
Continue the stock analysis
Jump to another research area for this company.